Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinellia exosomes are plant-derived extracellular vesicles extracted from the Chinese herb *Pinellia ternata*. These exosomes function as a nano-therapeutic agent that targets both lung cancer cells and tumor-associated macrophages (TAMs) within the tumor microenvironment. Their primary mechanism of action involves the simultaneous inhibition of multiple serine synthesis-related genes, including PHGDH (phosphoglycerate dehydrogenase), PSAT1 (phosphoserine aminotransferase 1), and PSPH (phosphoserine phosphatase). By suppressing these enzymes, Pinellia exosomes promote the polarization of macrophages toward the anti-tumor M1 phenotype and directly inhibit the proliferation of lung cancer cells, particularly those with high metabolic reliance on the serine synthesis pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pinellia exosomes.